首页 / 产品 / 蛋白 / 其他蛋白

Recombinant Human COL6 protein

  • 中文名: VI型胶原(COL6)重组蛋白
  • 别    名: COL6;Collagen alpha-1(XIX) chain
货号: PA2000-789DB
Price: ¥询价
数量:
大包装询价

产品详情

纯度>90%SDS-PAGE.
种属Human
靶点COL6
Uniprot No Q8LG76
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间1-406aa
氨基酸序列MMKSLASAVG GKTARACDSC VKRRARWYCA ADDAFLCHAC DGSVHSANPL ARRHERVRLK SASAGKYRHA SPPHQATWHQ GFTRKARTPR GGKKSHTMVF HDLVPEMSTE DQAESYEVEE QLIFEVPVMN SMVEEQCFNQ SLEKQNEFPM MPLSFKSSDE EDDDNAESCL NGLFPTDMEL AQFTADVETL LGGGDREFHS IEELGLGEML KIEKEEVEEE GVVTREVHDQ DEGDETSPFE ISFDYEYTHK TTFDEGEEDE KEDVMKNVME MGVNEMSGGI KEEKKEKALM LRLDYESVIS TWGGQGIPWT ARVPSEIDLD MVCFPTHTMG ESGAEAHHHN HFRGLGLHLG DAGDGGREAR VSRYREKRRT RLFSKKIRYE VRKLNAEKRP RMKGRFVKRS SIGVAH
预测分子量46 kDa
蛋白标签His tag N-Terminus
缓冲液PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于COL6重组蛋白的3篇参考文献示例(注:内容为虚构,仅供参考格式):

1. **文献名称**: "Recombinant collagen VI production in mammalian cells and its role in extracellular matrix assembly"

**作者**: Smith A, et al.

**摘要**: 研究利用HEK293细胞表达重组人胶原蛋白VI,优化纯化方法并证实其能正确组装成微纤维,支持其在细胞黏附中的作用。

2. **文献名称**: "Structural characterization of recombinant collagen VI domains reveals key interactions for network formation"

**作者**: Zhang L, et al.

**摘要**: 通过X射线晶体学解析重组COL6的C端球状结构域,阐明其与整合素结合的分子机制,为治疗COL6相关肌病提供结构基础。

3. **文献名称**: "A Drosophila model expressing recombinant collagen VI demonstrates mitochondrial dysfunction in muscular dystrophy"

**作者**: Lee H, et al.

**摘要**: 在果蝇中表达突变型COL6重组蛋白,发现其导致线粒体自噬异常,提示COL6缺陷通过能量代谢途径引发肌营养不良。

4. **文献名称**: "High-yield production of recombinant collagen VI in Pichia pastoris for tissue engineering applications"

**作者**: Costa R, et al.

**摘要**: 开发毕赤酵母表达系统高效生产重组COL6.证实其生物相容性,可用于构建促进成肌细胞分化的3D水凝胶支架。

(注:以上文献为示例,实际文献需通过PubMed或Google Scholar检索关键词如"recombinant collagen VI"获取。)

背景信息

Collagen type VI (COL6) is a unique extracellular matrix (ECM) protein that plays critical roles in tissue integrity, cell-matrix interactions, and mechanotransduction. It is a heterotrimeric protein composed of three genetically distinct α-chains (α1. α2. α3) encoded by *COL6A1*, *COL6A2*, and *COL6A3* genes. COL6 assembles into beaded microfibrils, forming a distinct network that bridges cells with larger collagen fibrils in connective tissues. It is widely expressed in skeletal muscles, skin, tendons, and cartilage, contributing to tissue resilience and regulating cellular behaviors such as adhesion, migration, and survival.

Mutations in COL6 genes are linked to hereditary disorders like Ullrich congenital muscular dystrophy and Bethlem myopathy, characterized by muscle weakness, joint contractures, and skin abnormalities. These conditions underscore COL6’s importance in maintaining musculoskeletal integrity. Recombinant COL6 proteins are engineered to study its structure-function relationships, disease mechanisms, and therapeutic interventions. Produced using mammalian or insect cell systems, these proteins retain post-translational modifications (e.g., hydroxylation, glycosylation) essential for biological activity.

Recombinant COL6 facilitates *in vitro* modeling of ECM dynamics, drug screening for collagen-related diseases, and tissue engineering applications. Its high purity and consistency overcome limitations of tissue-derived collagen, enabling standardized research. Recent efforts also explore its potential in regenerative medicine, such as developing bioactive scaffolds for muscle repair. As COL6 dysregulation is implicated in fibrosis and cancer progression, recombinant variants serve as tools to dissect pathological pathways and validate therapeutic targets, including gene therapies or protein replacement strategies for COL6-deficient disorders.

客户数据及评论

折叠内容

大包装询价

×